Richa Chandra
Tanzania
Research Article
Relative Bioavailability of a Fixed-Combination Tablet Formulation of
Azithromycin and Chloroquine in Healthy Adult Subjects
Author(s): Qinying Zhao, Vivek Purohit, Jenny Cai, Robert R. LaBadie and Richa ChandraQinying Zhao, Vivek Purohit, Jenny Cai, Robert R. LaBadie and Richa Chandra
A fixed-dose combination of azithromycin and chloroquine (AZCQ) is in development for intermittent preventive treatment of malaria in pregnant women (IPTp). The combination has demonstrated synergistic activity against chloroquine-resistant strains of Plasmodium falciparum in vitro and in vivo and efficacy in Phase 2 and 3 treatment studies in patients with symptomatic uncomplicated P. falciparum malaria. This was an open-label, randomized, single-dose, parallel-group study to estimate the relative bioavailability of two AZCQ tablets, each containing azithromycin base 250 mg and chloroquine base 155 mg (test treatment), compared with the coadministration of commercially available individual tablets of azithromycin base 500 mg and chloroquine base 300 mg (reference treatment) in 40 healthy male and female subjects (aged 18-55 years; body weight >50.0 kg). Fasting subjects were rando.. View More»
DOI:
10.4172/jbb.1000127